Based just outside of Seoul, South Korea, the GC company is formed...
GC Company Established
Based just outside of Seoul, South Korea, the GC company is formed to achieve its mission- developing critical specialty pharmaceuticals, improving healthcare globally.
History was marked this year as GC established itself as one of the pioneers of plasma in Asia.
GC began production of an antihemophilic factor (AHF) targeting Hemophilia A.
Production of GC’s Hemophilia Portfolio Begins
GC began production of an antihemophilic factor (AHF) targeting Hemophilia A. In Hemophilia A (factor VIII deficiency) the body doesn’t make enough factor VIII, one of many substances needed to form a blood clot. GC provided AHF to the South Korean Red Cross, free to the public through 1980 to improve public health throughout the country. GC- Devoted to Healthy Lives.
There are over 350 Primary Immunodeficiencies recognized by the World Health Organization.
IV- Globulin Developed
There are over 350 Primary Immunodeficiencies recognized by the World Health Organization. GC began production of IVIG to treat lives affected by these conditions throughout South Korea and has since exported IVIG to over 50 countries.
GC enters the hepatitis B vaccine marketplace in Asia. After 12 years of research, GC releases Hepavax reducing the rate of Hepatitis B throughout the South Korean population.
GC establishes the Mogam Institute for Biomedical Research in South Korea, furthering its investment in research and development.
GC is first in the world to release a vaccine in response to the hemorrhagic fever epidemic.
GC establishes the South Korea Hemophilia Foundation (KHF).
GC establishes a patient support foundation- the South Korean Hemophilia Foundation (KHF)
GC establishes the South Korea Hemophilia Foundation (KHF). The mission is to support the management and treatment of people with hemophilia, while assisting with the prevention, treatment, and rehabilitation.
GC continues its focus and expansion in the vaccine marketplace and develops Suduvax-varicella vaccine in South Korea. The varicella vaccine protects against chickenpox, which is caused by the varicella-zoster virus. Suduvax is the first varicella vaccine produced in South Korea and the second vaccine produced in the world, further establishing GC as a leader in the Asian vaccine marketplace.
GC sets up GC America (GCAM), to acquire, plasma collection centers.
GC establishes new Plasma Centers in the US with the licensing of the GCAM-Plasma division
GC sets up GC America (GCAM), to acquire, plasma collection centers. The company has continued to expand its plasma collection facilities, ensuring a stable supply of plasma for its future pharmaceutical products in the US.
Recombinant product GreenGene-F - approved for the treatment of Factor VIII disease in South Korea.
GC now produces a genetically encoded protein product to complement its portfolio of hemophilia and plasma-derived products in Asia.
Hunter Syndrome also called mucopolysaccharidosis II, or MPS II, is a rare genetic disorder mainly affecting boys. With Hunter Syndrome, the body cannot break down a specific sugar that is required to build bones, skin, tendons, and other tissue.
Hunterase gains approval in South Korea for the treatment of Hunter Syndrome
Hunter Syndrome also called mucopolysaccharidosis II, or MPS II, a rare genetic disorder mainly affecting boys. With Hunter Syndrome, the body cannot break down a specific sugar that is required to build bones, skin, tendons, and other tissue. It results in a life expectancy of 10-20 years for those with a severe case and up to 60 years in milder cases. Hunterase is an enzyme replacement therapy that improves many of the signs and symptoms of Hunter Disease, as well as the overall wellbeing of MPS II patients.
GC completes a state-of-the-art R&D center. The new research facility is the cornerstone of GC’s future.
GC receives approval in South Korea for the injectable drug Neulapeg used in the treatment of neutropenia.
GC completes the US- based study and publishes “Efficacy, Safety, and Tolerability of IVIG-SN in Patients with Primary Immunodeficiency.”
An eleven investigator, multi-center IVIG trial is completed in the US. Immunologists, Mark Stein, Richard Wasserman et al. establish that IVIG-SN is safe and efficacious in the treatment of Primary Humoral Immune Deficiency.
GC establishes a strategic foothold by building its first plasma manufacturing facility in Montreal, Canada.
GC establishes its first plant to manufacture plasma protein therapies in Canada.
GC establishes a strategic foothold by building its first plasma manufacturing facility in Montreal, Canada. GCBT is a new state-of-the-art facility, spanning 250,000 sq. ft. The facility will manufacturer IVIG and other plasma- based products for future distribution into Canada and the US.
GC establishes a new research and development company focused on vaccine development in Seattle, WA. GC builds a strategic collaboration and partnership with global health organizations to form the new company.
Executing on their vision as a global leader, GC opens a new research and development company based in San Diego, California. Artiva’s primary focus is in natural killer cell therapy research.
GC executes on its vision as a global leader in healthcare and establishes GC Biopharma USA, Inc. within the US. Design and construction of its new corporate office is completed in Fort Lee, New Jersey. GC Biopharma USA, Inc. starts the commercialization process to launch IVIG.